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Thrombophilia is a disorder caused by inherited and acquired 
defects and is defined as a predisposition to thrombosis (1). 
The most common cause of acquired thrombophilia is the 
antiphospholipid syndrome (APS). Inherited thrombophilia 
constitutes a group of abnormalities of blood coagulation, 
including the factor V Leiden mutation (FVL) (homozygous 
or heterozygous), the prothrombin (FII) G20210A mutation 
(Pm) (homozygous or heterozygous), and deficiencies of 
the endogenous anticoagulants, antithrombin (AT), protein 
C, and protein S. Among these conditions, FVL and Pm are 
relatively common, while the others are rare. FVL is a point 
mutation (G1691A), resulting in an altered factor resistant 
to inactivation by protein C. The Pm leads to a 20%–50% 
increase in plasma prothrombin levels (2, 3).
The prevalence of inherited thrombophilia in the general 
western population is estimated to be approximately 15% 
(4). However, it seems that there is a significant variation 
in the prevalence of these conditions among different 
geographical and tribal populations. FVL varies from 0.6% 
to 7.0%, with the lowest frequency observed in Africa (0%–
0.6%) and the highest in Southern Europe (7%). The mean 
prevalence in Northern Europe is 4%. The prevalence of Pm 
varies from 0.2% to 3%, being lowest in Africa (0%–0.3%) 
and highest in Southern Europe (3%). The mean value in 
Northern Europe is 2%. Protein C, protein S, and AT defi-
ciencies are extremely rare (0.2%–0.4%, 0.03%–0.1%, and 
0.02%–0.2%, respectively) (5).
The role of inherited thrombophilia in pregnancy loss and 
vascular gestational disorders has been investigated in sev-
eral studies, and the results seem to be contradictory. The 
aim of this review was to elucidate the association of inher-
ited thrombophilia and reproductive disorders. The value of 
screening women for inherited thrombophilia and the treat-
ment options during pregnancy are also discussed.
The association between inherited thrombophilia and 
reproductive disorders
1. Inherited thrombophilia and infertility
Coulam et al. (6) reported that a prothrombotic tendency is 
associated with unexplained infertility, but this finding was not 
in agreement with data from Casadei et al. (7). To date, there 
has been no conclusive evidence in the literature to suggest an 
association of inherited thrombophilia and infertility other than 
recurrent implantation failure (8). Di Nisio et al. (9) conducted 
a systematic review and meta-analysis of all the available 
studies on the role of inherited thrombophilia in implantation 
failure. A significant association was found only for FVL [Odds 
ration (OR) 3.08; 95% confidence interval (CI) 1.77–5.36]. 
2. Inherited thrombophilia and recurrent pregnancy loss
It is estimated that approximately 25% of conceptions and 15% 
of all clinically recognized pregnancies end in a miscarriage 
(10, 11). Moreover, three or more successive losses affect 
1%–2% of women of reproductive age, and two or more suc-
cessive losses affect approximately 5% (12). Although several 
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causes of recurrent pregnancy loss have been identified, 38% of 
cases remain unexplained (13, 14). Thrombophilias have been 
suggested as a possible cause of recurrent miscarriage (RM) (15).
The hypothesis that inherited thrombophilia may be associ-
ated with miscarriage was first investigated by the European 
prospective cohort of thrombophilia (EPCOT) (16). The authors 
observed an increased risk of pregnancy loss in 571 women 
with inherited thrombophilia (ΟR 1.35; 95% CI 1.01–1.82). 
In 2003, Rey et al. (16) conducted a meta-analysis of the data 
on the association of inherited thrombophilia and RM. They 
found a significant variability among studies in the definition 
of RM and the gestational period that miscarriage occurred. A 
significant association was identified for FVL, Pm, and protein S 
deficiency with non-recurrent and recurrent fetal loss. Protein C 
and AT deficiencies were not associated with RM; however, this 
result should not be considered conclusive because of their low 
prevalence in the general population. 
A year later, Kovalevsky et al. (17) published the results of anoth-
er meta-analysis, investigating the role of the two most common 
forms of inherited thrombophilia (FVL and Pm) in RM. The analy-
sis reported significant among-study heterogeneity for FVL, but 
not for Pm. However, they did establish an association between 
FVL, Pm, and RM, with the carriers having a double risk for RM 
compared with women without thrombophilia. Finally, limiting 
the data to women with first-trimester recurrent pregnancy loss 
(RPL) appeared to weaken the association in the FVL analysis. 
Such an effect was not observed in the G20210A analysis. 
The most recent and well-designed review on the association 
of inherited thrombophilia and RM was conducted by Rodger 
et al. (18) who reported an increased risk for miscarriage for 
women with FVL (OR 1.52; 95% CI 1.06–2.19), but no associa-
tion was found for Pm.
Although it appears that the results of the published studies are 
conflicting, most reviews suggest an association of RM with FVL 
and Pm.
3. Inherited thrombophilia and late pregnancy loss
Kovalevsky et al. (17) also analyzed the association of inherited 
thrombophilia with loss at different stages of the pregnancy. 
Late loss was defined as a pregnancy being lost after its 13th 
week. They found that FVL was associated with early and late 
loss. Pm was associated with late loss and recurrent early loss 
but not isolated early loss. Protein S deficiency was also associ-
ated with late loss and early recurrent loss. AT and protein C 
deficiencies were not associated with pregnancy loss. 
In a systematic meta-analysis (19) where late loss was defined 
as pregnancy loss after the 24th week, there was a significant 
risk for early loss in homozygous FVL but a lower, non-signifi-
cant risk in heterozygous FVL or Pm. With respect to late loss 
(3rd trimester), there was a significant risk in heterozygous FVL 
and a lower, non-significant risk in heterozygous Pm. Although 
there was a higher risk for late loss in women with protein S 
deficiency, no such increase in risk was found for protein C 
and AT deficiency for early or late loss. Inherited AT deficiency 
which occurs in two forms (Type I: low antigen concentrations 
and activity; Type II: normal antigen concentrations, low activi-
ty) is associated with an increased risk of VTE and adverse preg-
nancy outcome as well (20). Type II AT deficiency associated 
with a defect at the heparin binding site (HBS) due to Leu99Phe 
mutation is a subtype that in its heterozygous form represents a 
minor risk for thrombosis, while homozygous carriers are prone 
to a high risk for early onset of arterial and venous thrombosis 
and pregnancy loss, despite anticoagulation with heparin (20).
Overall, it seems that FVL and Pm are more strongly associated 
with late loss (2nd and 3rd trimester) than early loss (1st trimes-
ter), whereas protein S deficiency seems to be significantly 
associated only with late loss.
4. Inherited thrombophilia and pre-eclampsia 
A number of small studies have investigated the contribu-
tion of thrombophilia in the pathogenesis of pre-eclampsia 
(2, 21, 22). Mello et al. (23) conducted a large multicenter 
case-control study to assess the prevalence of thrombophilic 
defects in women with severe and mild pre-eclampsia. There 
was a significant association between Pm with mild or severe 
pre-eclampsia and FVL with severe pre-eclampsia. There was 
no relationship between protein C, protein S, and AT defi-
ciency with pre-eclampsia, but the number of the subjects with 
such defects was too small to allow for definite conclusions. 
Moreover, a significant increase was reported in the incidence 
of early onset of pre-eclampsia (<28 weeks gestation) and 
disseminated intravascular coagulation [but not of hemoly-
sis elevated liver enzymes low platelets (HELLP) syndrome, 
eclampsia, and pulmonary edema] in women with thrombo-
philia compared with the controls (23).
However, the most recent meta-analysis of Rodger et al. (18) 
did not observe any significant association between FVL and 
Pm with pre-eclampsia. Facchinetti et al. (24) studied the risk of 
recurrence of pre-eclampsia as well as the perinatal outcome 
following pre-eclampsia according to the presence or absence 
of thrombophilia in the mother. The rate of recurrence was 
51.9% in women with inherited thrombophilia compared with 
only 25.9% in women without thrombophilia.
5. Inherited thrombophilia and intrauterine growth retardation 
(IUGR)
Wu et al. (19) found that embryos from homozygous FVL and 
heterozygous Pm mothers had an increased risk for IUGR. None 
of the other inherited prothrombotic defects were associated 
with IUGR in that study. Rodger et al. (18) failed to confirm the 
results by Wu et al. (19) because they reported no significant 
risk for IUGR in women tested positive for FVL or Pm.
6. Inherited thrombophilia and placental abruption
Wu et al. (19) reported a significant risk for placental abrup-
tion in pregnant women heterozygous for FVL (OR 4.70; 95% 
CI 1.13–19.59) or Pm (OR 7.71; 95% CI 3.01–19.76). This result 
however was questioned in the meta-analysis by Rodger et al. 
(18) who found no significant risk for placental abruption in 
women with FVL or Pm.
7. Inherited thrombophilia and VTE
It is well known that pregnancy is a thrombogenic condition, 
and the risk for VTE (deep venous thrombosis or pulmonary 
embolism) is significantly increased when additional prothrom-
botic factors coexist. The prevalence for VTE is gradually 
J Turk Ger Gynecol Assoc 2016; 17: 45-50
Liatsikos et al.
Thrombophilia and recurrent pregnancy loss46
increased from 1/1000 pregnancies (when no other prothrom-
botic conditions exist) to 1/500 for heterozygous FVL women, 
1/200 for heterozygous Pm, 4.6/100 for double heterozygous FVL/
Pm, 1/113 for protein C deficiency, and 1/2.8 for AT deficiency 
(5). According to the findings of Wu et al. (19), all inherited pro-
thrombotic conditions significantly increased the risk for VTE.
In summary, there is preliminary evidence to suggest that FVL 
and Pm are associated with second or third trimester loss, with 
insufficient evidence for the association with pre-eclampsia and 
IUGR. There is a need for larger, well-designed prospective trials. 
The association of different types of inherited thrombophilia 
and reproductive disorders is summarized in Table 1.
Is screening women for inherited thrombophilia prior to 
pregnancy necessary?
At present, there is no evidence to support universal screen-
ing for inherited thrombophilia prior to conception. Selective 
screening should be considered on the basis of family history 
of thrombosis or adverse reproductive history.
The National Society of Genetic Counselors in its guidelines 
for the genetic evaluation and counseling of couples with 
recurrent miscarriage adopted a more selective attitude for 
thrombophilia screening, including a personal or family his-
tory of VTE in its criteria. They suggested testing for FVL and 
Pm for all women with recurrent pregnancy loss. Until the 
results of further studies are published, testing for protein 
C, protein S, and AT deficiencies should be offered only to 
women with a personal/family history of VTE. Finally, full 
thrombophilia screening [AT, protein C, protein S, FVL muta-
tion and APC Resistance Assay (APCR), Prothrombin Gene 
Mutation (G-20210-A, Lupus Anticoagulant (LA) and Anti-
Cardiolipin antibodies (ACLA)] should be offered to women 
with RM and a common thrombophilic defect (FVL or Pm) 
diagnosed previously because the co-existence of another 
defect dramatically increases the risk for VTE and pregnancy 
complications (25, 26). 
The American College of Obstetricians and Gynecologists 
(ACOG) did not recommend screening for inherited throm-
bophilia for women with a history of recurrent fetal loss or 
placental abruption because it is unclear whether anticoagu-
lation treatment reduces the risk of recurrence. There is also 
insufficient evidence to support screening for thrombophilias in 
women with a history of IUGR or pre-eclampsia (27). 
The Royal College of Obstetricians and Gynaecologists (RCOG) 
however recommended screening for inherited thrombophilia 
for women with second-trimester miscarriage. Testing should 
include FVL, Pm, and protein S (28).
Although there is no universal agreement on screening for 
inherited thrombophilia in reproductive disorders, a proposed 
screening strategy is outlined in Table 2.
Treatment 
Antithrombotic agents could potentially increase the live-birth 
rate of subsequent pregnancies in women with inherited 
thrombophilia and RM or late loss, but the results of the studies 
investigating their role in the management of these conditions 
are controversial.
The treatment of inherited thrombophilia associated with 
reproductive disorders is governed by two considerations. The 
first is the prevention of venous thrombosis during pregnancy, 
which itself is a hypercoagulable state. Some practitioners 
would offer heparin treatment shortly after a pregnancy has 
been confirmed, whereas others offer heparin treatment only 
in the third trimester or just post-partum. The second consider-
ation relates to the beneficial effect of treatment on pregnancy 
outcome. In this situation, the treatment will need to be started 
at a specific time of the pregnancy to improve the desired out-
come. For example, if the intention of treatment is to reduce 
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Table 1. Association between different types of inherited thrombophilia with pregnancy loss and a variety of pregnancy 
complications
 FVL  Pm Prot C def.  Prot S def.  AT def. 
Recurrent implantation failure  −/+  −  0  0  0 
Recurrent 1st trimester loss (≥3)  +  +  0  0  0 
2nd or 3rd trimester loss +  +  0  +  0 
Pre-eclampsia  −/+  −/+  0  0  0 
IUGR  −/+  −/+  0  0  0 
Placental abruption −/+ −/+ 0  0  0 
VTE ++  ++  +  +  ++ 
 0 Insufficient published data 
 − No association
 −/+ Published data contradictory for an association
 + Weak association
 ++ Strong association 
FVL: factor V Leiden mutation; Pm: G20210A mutation; Prot C def.: protein C deficiency; Prot S def.: protein S deficiency; AT def.: antithrombin defi-
ciency; IUGR: intrauterine growth retardation; VTE: venous thromboembolism
the risk of recurrent first trimester loss, the treatments need to 
be started as soon as a pregnancy has been confirmed. If the 
intention of treatment is to prevent late loss or to reduce late 
pregnancy complications such as pre-eclampsia or IUGR, then 
the treatment should be started in the second trimester. There 
is much debate however about the likely benefit of heparin 
treatment on the outcome. Based on data extrapolated from 
the observation of the association (described earlier), it seems 
reasonable to offer treatment with heparin to women with FVL 
and Pm with recurrent or late pregnancy loss. 
According to the ACOG and RCOG guidelines, there was insuf-
ficient clinical evidence that prophylaxis with unfractioned 
heparin or low molecular weight heparin (LMWH) prevents 
recurrence in women who had experienced miscarriage or pla-
cental abruption or IUGR. Although ACOG strongly discouraged 
the administration of any anticoagulation treatment in such 
cases, RCOG suggested that heparin therapy during pregnancy 
improves the outcome of women with mid-trimester miscar-
riage associated with inherited thrombophilias (27, 28). 
The use of antithrombotics in pregnancy has to be monitored and 
evaluated for safety. The possibility of these agents causing more 
harm than good in these patients cannot be excluded. In contrast 
to coumarin derivatives, unfractionated heparin and LMWH do 
not cross the placenta; therefore, they do not have the potential 
to cause fetal bleeding or teratogenicity (29). Potentially serious 
maternal risks associated with heparin include bleeding, heparin-
induced osteopenia, and heparin-induced thrombocytopenia. 
These risks are greater for unfractionated than LMWH.
Kaandorp et al. (30) compared the risk for maternal and neo-
natal adverse events between pregnant women who did not 
receive any anticoagulation treatment with those who received 
aspirin only or aspirin plus nadroparin. No significant increase 
in the risk of serious maternal complications or neonatal prob-
lems was observed. However, minor side effects, such as bruis-
ing and swelling or itching at the injection site were more com-
mon in women who received treatment. Similar results were 
reported in the Scottish Pregnancy Intervention (SPIN) trial (31).
LMWH is as effective and safe as unfractionated heparin, with 
potential advantages in pregnancy, because it is less associated 
with thrombocytopenia and osteoporosis and it can be admin-
istered once daily (longer half-life). Low dose aspirin (less than 
150 mg/day) also appears to be safe, while the safety of higher 
doses of aspirin during the first trimester is uncertain (29, 32). 
In a multicenter randomized control trial (RCT), 139 pregnant 
women with inherited thrombophilia without antiphospholipid 
antibodies at <12 weeks of gestation were recruited from all 
university hospitals in the Netherlands, two university hospitals 
in Australia, and one university hospital in Sweden as well as 
from six non university/teaching hospitals in the Netherlands 
between December 2000 and 2009. Either daily LMWH (dalte-
parin, 5000 IU weight adjusted dosage) with aspirin 80 mg or 
aspirin 80 mg alone were administrated. According to the results 
of this trial, named FRUIT, adding LMWH to aspirin before 12 
weeks gestation seems to reduce recurrent hypertensive disor-
ders (HD) in women with previous early-onset HD and/or small 
for gestational age (SGA) in the context of an inheritable throm-
bophilia without antiphospholipid antibodies (33).
Between February 2000 and September 2012, the Thrombophilia 
in Pregnancy Prophylaxis Study (TIPPS) was conducted in 36 
tertiary care centers in Canada, Australia, the USA, the UK, and 
France. In this open label randomized trial, 289 pregnant women 
with thrombophilia who were at an increased risk of placenta-
mediated pregnancy complications, venous thromboembolism, 
or both were included. Women received either antepartum 
dalteparin 5000 international units (IU) once daily by subcutane-
ous self-injection from the day of randomization until 20 weeks 
of gestation followed by 5000 IU twice daily from 20 weeks until 
at least 37 weeks gestational age or no antepartum dalteparin. 
Antepartum dalteparin was not found to reduce the risk of 
either pregnancy loss, venous thromboembolism, or placenta-
J Turk Ger Gynecol Assoc 2016; 17: 45-50
Liatsikos et al.
Thrombophilia and recurrent pregnancy loss48
Table 2. Recommendations on screening for inherited thrombophilia in women with a history of pregnancy loss and a 
variety of pregnancy complications
 FVL  Pm Prot C def.  Prot S def.  AT def. 
Recurrent implantation failure −  −  −  −  − 
Recurrent 1st trimester loss (≥3) +  +  +  +  + 
2nd or 3rd trimester loss +  +  +  +  + 
Pre-eclampsia + (1)  + (1)  −  −  − 
IUGR  + (2)  + (2)  −  −  − 
Placental abruption + (2)  + (2)  −  −  − 
VTE +  +  +  +  + 
 − Screening not recommended
 + Screening recommended
  (1)   In recurrence or early-onset
  (2)   After the exclusion of common causes
FVL: factor V Leiden mutation; Pm: G20210A mutation; Prot C def.: protein C deficiency; Prot S def.: protein S deficiency; AT def.: antithrombin defi-
ciency; IUGR: intrauterine growth retardation; VTE: venous thromboembolism
mediated pregnancy complications in pregnant women with 
thrombophilia [dalteparin 25/146 (17.1%; 95% CI 11.4%–24.2%) 
vs no dalteparin 27/143 (18.9%; 95% CI 12.8%–26.3%); risk differ-
ence −1.8% (95% CI 10.6%–7.1%)]. This was the first large trial to 
show no benefit of LMWH administration in this high risk group 
of pregnant women. Moreover, researchers found that delte-
parin administration was associated with an increased risk of 
minor bleeding and noted LMWH administration complications. 
Lastly, a meta-analysis was conducted showing low evidence 
to support that LMWH might prevent recurrent severe placenta-
mediated pregnancy complications (34).
As a conclusion, the use of LMWH and aspirin during pregnancy 
is considered safe, with only minor side effects.
Should women with inherited thrombophilia be referred to a 
hematologist?
Most general obstetricians and gynecologists today are familiar 
with common prothrombotic disorders, and they are capable 
of investigating and diagnosing common forms of thrombo-
philia. In addition, specialists in RM and high-risk pregnancies 
often have the skills to undertake the management of pregnant 
women with thrombophilia. 
RCOG advises that the opinion of a local expert should be 
sought for women with AT deficiency, those with more than 
one thrombophilic defect, or those with additional risk factors. 
Women with AT deficiencies (particularly type 1 with reduc-
tions in both activity and antigen) have a high risk of recurrence 
and may require higher doses of LMWH or AT concentrate 
during pregnancy. They are also likely to be on long-term anti-
coagulation treatment with warfarin. Such conditions should 
be managed in collaboration with a hematologist expert in 
thrombosis (35). 
The recommendations on the treatment of pregnant women 
diagnosed with sole or multiple thrombophilic defects in 
conjunction with a history of reproductive disorders are sum-
marized in Table 3.
Ongoing trials
There are two ongoing RCTs investigating the efficacy and safe 
dose of LMWH in pregnancy (36).
The first one is The Highlow study (NCT Clinicaltrials.gov 
01828697). It is an investigator-initiated, randomized-controlled, 
open-label trial that aims to provide high-quality evidence 
on the optimal prophylactic dose of LMWH in pregnancy in 
women with a history of VTE, comparing two different doses 
of LMWH (36).
The second one, the ALIFE2 study (NTR 3361) is an open-label 
trial, including women with inherited thrombophilia (FVL, 
Pm, AT deficiency, protein C deficiency, protein S deficiency, 
or a combination) and two or more miscarriages. The effect 
of LMWH (enoxaparin 40 mg) on live birth and on adverse 
pregnancy outcomes (e.g., pre-eclampsia, HELLP syndrome, 
intra-uterine growth restriction, placental abruption, premature 
delivery, and congenital malformations) and adverse effects 
of treatment (hemorrhagic episodes, thrombocytopenia, and 
allergic skin reactions to LMWH) are being studied (36).
Conclusion
FVL is associated with repeated implantation failure, RM, and 
late loss. Pm is associated with RM and late loss. Protein S defi-
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Table 3. Recommendations on the treatment of pregnant women with inherited thrombophilia and a history of pregnancy 
loss or pregnancy complications
 High-risk thrombophilia    
 (FVL +/+, Pm +/+, FVL/Pm,                             Low-risk thrombophilia 
	 AT	def.)	 											FVL	+/−					Pm	+/−						Pr.	C	def.				Pr.	S	def.	
Recurrent implantation failure 3  1  1  1  1 
Recurrent 1st trimester loss (≥3)  3  2  2  2  2 
2nd or 3rd trimester loss 3  2  2  2  2 
Pre-eclampsia 3  2  2  1  1 
IUGR  3  2  2  1  1 
Placental abruption 3  2  2  1  1 
VTE:             Once 4  3  3  3  3
                      Recurrent (≥2)  4  4  4  4  4 
 1: Intense surveillance during pregnancy, graduated compression stockings
 2: Prophylactic dose LMWH (empirical treatment until further data available) 
 3: Prophylactic dose LMWH. expert advice, referral to a specialist hematologist  or joint  
 antenatal-hematology clinic
 4: Prophylactic or therapeutic dose LMWH. Referral to a specialist hematologist or joint  
 antenatal-hematology clinic
FVL: factor V Leiden mutation; Pm: G20210A mutation; Prot C def.: protein C deficiency; Prot S def.: protein S deficiency; AT def.: antithrombin defi-
ciency; IUGR: intrauterine growth retardation ; VTE: venous thromboembolism; LMWH: low molecular weight heparin 
ciency is associated with late loss. There is insufficient evidence 
to suggest an association of other forms of inherited throm-
bophilia and reproductive disorders. Screening and treatment 
strategies based on the observed association seem reasonable, 
although there is as yet no firm evidence (such as RCTs) to 
confirm the benefits of treatment. 
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